Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter.
But two have already disappointed, and the third has shown little to suggest a positive outcome.
A decent showing for Pfizer/Roche in haemophilia sets up a rivalry with Uniqure/CSL, and a smattering of deals get done before the year end – and before JP Morgan.
Will biotech lead a bull market recovery? Will Novartis spin off its cell therapy business? Read on for some of your leftfield predictions for biopharma.
Sunlenca gets a US green light at the second time of asking, but combination success will be vital to it fulfilling its promise.
But, as Celyad bows out, how do you compete in a field as crowded as this?
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.